Advertisement
Based on extensive clinical trials, isosorbide mononitrate sustainedrelease tablet has shown optimistic results in a study of 1,350 patients withangina who received the drug for over six months. Lotus plans to release thedetails of the study, and expects to launch the drug pending the approval fromSFDA in 2009. Approximately 0.4 to 0.8 million people in China suffer fromangina and that figure is anticipated to grow over the coming years due toincreases in the aging population. Lotus estimates it will achieve a 10% to20% market share within two years of launching the drug and a 30% market sharewithin three years.
Advertisement
The drug dilates the blood vessels and lowers the blood pressure.AstraZeneca sells the drug under the trade name Imdur. The components of thedrug include matrix tablets, isosorbide mononitrate, andhydroxypropylmethylcellulose (HPMC). Both components are available at low costand the tablet is easy to manufacture in large scale, which may result in highprofit margins for Lotus.
"We have achieved significant milestones for the development of theisosorbide mononitrate sustained release tablet in both pre-clinical trialsand manufacturing capabilities," said Dr. Zhongyi Liu, Chairman, CEO andPresident of Lotus Pharmaceuticals, Inc. "We look forward to introducing thisdrug, which will diversify the portfolio of our major drugs."
About Lotus Pharmaceuticals, Inc.
Lotus Pharmaceuticals, Inc. ("Lotus") controls and operates LiangfangPharmaceutical, Ltd. ("Liangfang") and Enze Jiashi Pharmaceutical, Ltd.("Enze"), two Chinese pharmaceutical companies located in Beijing. Liangfangand Enze form a large comprehensive enterprise, which deals in an integrationof the production, trade, sales and marketing of pharmaceuticals. Together,they possess some of the most advanced pharmaceutical-production equipmentused in China, workshops authenticated by the National GMP, a suite of variousmedicines produced by Liangfang and/or Enze (together, "Lotus East"), and anumber of high-tech personnel. Lotus East has business and office facilitiesof 2,000 square meters, warehouse of 1,000 square meters and operates tenretail pharmacies in the Beijing area. Lotus East performs scientific researchon new medicines, and the production, wholesale and retail sale of medicines.For more information, visit http://www.LotusEast.com.
Safe Harbor Statement
This press release contains "forward-looking statements" within themeaning of the "safe-harbor" provisions of the Private Securities LitigationReform Act of 1995. Such statements involve known and unknown risks,uncertainties and other factors that could cause the actual results of theCompany to differ materially from the results expressed or implied by suchstatements, including changes from anticipated levels of sales, futurenational or regional economic and competitive and regulatory conditions,changes in relationships with customers, access to capital, difficulties indeveloping and marketing new products, marketing existing products, customeracceptance of existing and new products, and other factors. Additionalinformation regarding risks can be found in the Company's Annual Report onForm 10K filed with the SEC. Accordingly, although the Company believes thatthe expectations reflected in such forward-looking statements are reasonable,there can be no assurance that such expectations will prove to be correct. TheCompany has no obligation to update the forward-looking information containedin this press release.
SOURCE Lotus Pharma
